EllieMD Dihexa A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not The 2026 Biologics Wave: Which Innovations Will Break Through? Contract Pharma DIHEXA Research Capsules Peptide Tech FDA Drug Approval Decisions Expected in May 2026 MPR